Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 47Breast Neoplasms 45Colorectal Neoplasms 29Prostatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Pancreatic Neoplasms 18Lung Neoplasms 18Glioblastoma 18Melanoma 17Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Carcinoma, Hepatocellular 13Brain Neoplasms 13Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Multiple Myeloma 11Carcinoma, Renal Cell 11Triple Negative Breast Neoplasms 10Head and Neck Neoplasms 10Lymphoma 9Uterine Cervical Neoplasms 7Rectal Neoplasms 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Sarcoma 6Leukemia 6

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Microsatellite-stable Colorectal Cancer × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡